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Introduction
Embryonic stem (ES) cells are derived from the inner cell 
mass  of  the  blastocyst  and  can  be  maintained  in  a 
pluripotent  state  in  defined  conditions  in  both  human 
and  mouse  [1].  Theoretically,  ES  cells  can  differentiate 
into  every  somatic  and  germ  cell  type.  The  recent 
discovery that adult somatic cells can be reprogrammed 
into a pluripotent state (induced pluripotent stem (iPS) 
cells) [2,3] opens the way for the generation of patient-
specific  PS  cells,  which  would  overcome  rejection 
problems  associated  with  transplantation  of  ES  cell-
derived  tissues.  The  development  of  appropriate 
conditions to differentiate ES and iPS cells into a variety 
of cell types and tissues therefore holds major promise 
for future cell-replacement therapy. A major challenge in 
this  field  is  the  directed  differentiation  of  pluripotent 
cells into functional mature tissue [1, 4].
A relatively underinvestigated area is the generation of 
cells of the thymus from ES and iPS cells. The thymus is 
the  site  of  development  of  T  cells,  cells  essential  for 
adaptive immunity. In the thymus, a self-tolerant T-cell 
repertoire  is  established  through  positive  and  negative 
selection [5,6]. Very early hematopoietic precursors seed 
the  thymus  from  the  bone  marrow  to  initiate  T  cell 
development  [7].  Hence,  the  thymus  consists  of  a 
hematopoietic,  an  epithelial  and  a  mesenchymal 
component.  The  hematopoietic  component  includes 
developing T cells and mature dendritic cells [5-7]. The 
epithelial  component  includes  thymic  epithelial  cells 
(TECs),  which  have  two  subtypes:  cortical  (cTEC)  and 
medullary  (mTEC).  These  two  types  of  TECs  form  a 
three-dimensional  structure  together  with  endothelial 
cells, poorly defined mesenchymal cells, neural elements, 
neural  crest-derived  pericytes,  and  adipocytes  [5,  6]. 
Only  TECs  seem  to  be  essential,  as  purified 
undifferentiated  TECs  at  embryonic  day  (E)  12.5  can 
reconstitute  a  functional  thymus  after  aggregation  and 
transplantation under the kidney capsule [8-11]. During 
T-cell  maturation,  early  T-cell  precursors  enter  the 
thymus  and  undergo  expansion,  followed  by  cTEC-
dependent positive selection for high antigen affinity, and 
then  mTEC-  and  dendritic  cell-dependent  negative 
selection against strong autoantigen recognition [12].
Discussion
Rationale for the generation of TECS from pluripotent stem 
cells
There  are  several  reasons  to  pursue  the  derivation  of 
TECs from human pluripotent cells. First, they could be 
used to tackle the problem of T-cell reconstitution after 
hematopoietic  stem-cell  transplantation  (HSCT),  the 
only  curative  therapy  for  many  hematological 
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the  thymus  begins  to  involute,  and  the  production  of 
naïve  T  cells  decreases.  This  physiologic  atrophy  is 
exacerbated  by  conditioning  regimens  used  before 
translplant and by development of graft – versus – host 
disease after transplant [12-14]. Whereas post-transplant 
reconstitution of most hematopoietic lineages is relatively 
swift, T-cell reconstitution is delayed up to several years 
in  adult  recipients.  Even  if  absolute  T-cell  numbers 
recover, the full T-cell repertoire is rarely restored, which 
leads  to  increased  probability  of  relapse,  chronic  viral 
infection,  secondary  malignancy  and  vaccine  failure 
[12,13]. Interventions to preserve thymic integrity would 
allow for more robust T-cell recovery [12]. This becomes 
an  increasingly  important  issue  as  the  average  age  of 
transplant patients increases [12, 14]. Current approaches 
in  clinical  trials  include  administration  of  keratinocyte 
growth  factor  (KGF),  interleukin-7,  growth  hormone, 
and  chemical  castration  using  gonadotropin-releasing 
hormone analogues [12]. All have some clinical benefit 
but  sometimes  severe  side  effects.  Co-transplanting 
patient-specific  functional  thymic  tissue  would  almost 
certainly  result  in  long-term  benefit  and  enhanced 
survival.
A  second  potential  reason  is  the  attenuation  of 
immunological  aging  (Figure  1b).  It  is  widely 
hypothesized that improving thymic function in the older 
person will increase health, and perhaps extend life span 
[15-24].  Some  rather  old  reports  suggest  that 
transplantation  of  multiple  thymi  into  aged  animals  is 
beneficial for immune function, and increases mean, but 
not  maximal  life  span,  although  there  is  evidence  for 
significant mouse strain-dependent variation [22-24].
Congenital diseases in which a thymus is lacking are 
good candidates for thymus replacement therapy (Figure 
1c).  In  these  diseases,  correction  of  or  functional 
compensation  for  the  genetic  defect  during  in  vitro 
differentiation may allow transplantation of autologous, 
iPS-derived thymic tissue (Figure 1c). Loss of FOXN1, an 
essential gene for thymic development, causes the rare 
‘nude/severe  combined  immune  deficiency  (SCID)’ 
syndrome in which patients have no hair or thymus [25]. 
In  DiGeorge  syndrome  (DGS),  the  most  frequently 
diagnosed microdeletion in humans (1 in 4000 people), a 
region of chromosome 22 is monoallelically deleted. This 
region includes a crucial transcription factor required for 
the  early  stages  of  thymic  development,  TBX1.  The 
syndrome  (DGS/velofaciocardial  syndrome  (VFCS))  is 
characterized  by  absent  or  hypoplastic  thymus  and 
parathyroids, in addition to a variety of cardiac and facial 
malformations  [26,27].  In  both  syndromes,  allogeneic 
thymic  transplantation  has  been  beneficial  [28-30]. 
Obvious problems include the allogeneic nature of the 
graft and the scarcity of donors. In the particular case of 
thymus transplantation, this problem is exacerbated by 
the fact that thymi from donors that would otherwise be 
considered  young  have  already  undergone  severe  age-
related thymic atrophy.
A  final  clinical  rationale  is  the  treatment  of 
autoimmune  disease  (Figure  1d).  TECs  derived  from 
patient-specific iPS cells could be genetically modified to 
influence the process of positive and negative selection in 
the engrafted thymic tissue. For example, expression of a 
culprit autoantigen in the putative medullary cells of the 
graft  might  induce  tolerance  to  these  antigens  by 
mediating  negative  selection  of  the  immature  T  cells 
recognizing these antigens [6].
TECs derived from ES or iPS cells could also improve 
humanized mouse models (Figure 1e). A major challenge 
in immunology is the establishment of mouse models of 
the human immune system. Currently the best models 
are immunodeficient Rag1–/– ilr2g–/– or NOD-SCIDilr2g–/– 
mice  engrafted  neonatally  with  human  cord-blood 
hematopoietic stem and progenitor cells. In such mice, 
all major hematopoietic lineages are reconstituted, and 
even the structure of secondary lymphoid organs seems 
‘human’.  However,  human  T-cell  responses  are  weak 
except  for  alloreactivity,  and  peripheral  T-cell 
homeostasis  is  abnormal  [31-34].  An  improvement  of 
this model with more robust T-cell activity is the bone 
marrow/liver/thymus  (BLT)  mouse  [35,  36].  This  is  a 
non-obese  diabetic  (NOD)-SCIDilr2g–/–  mouse 
transplanted with a human fetal thymus and liver under 
the kidney capsule, and subsequently transplanted with 
fetal  liver  CD34+ progenitor  cells.  In  these  mice,  both 
innate  and  major  histocompatibility  complex  I  and  II-
restricted,  T-cell-dependent  immune  responses  were 
seen. Interestingly, all T-cell development occurred in the 
grafted  human  thymus,  not  in  the  endogenous  mouse 
thymus. These data suggest that the presence of human 
thymic  tissue  may  be  crucial  to  develop  a  humanized 
mouse. It follows that as TECs are the essential functional 
component of the thymus, ES or iPS-derived TECs could 
also be used to construct an improved humanized mouse 
model. In addition, by using patient-specific iPS cells, it is 
possible to capture in a mouse model some of the genetic 
diversity in disease susceptibility and immune responses 
among  humans.  Finally,  iPS  technology  will  allow 
cotransplantion of syngeneic human tissues (Figure 1e). 
In  such  a  mouse,  organ  or  tissue-specific  immune 
responses  in  the  context  of  autoimmunity  or  infection 
can  be  studied,  and  vaccines  can  be  tested.  The 
development  of  such  a  mouse  may  revolutionize 
translational research.
Generating pluripotent stem cell-derived TECs
To date, it has not been possible to generate TECs from 
human ES or iPS cells, but important steps towards this 
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region of the third pharyngeal pouch, and are therefore 
of  endodermal  origin  [5].  Subsequently,  the  tissue 
descends  to  the  precordial  region.  The  presumptive 
thymic epithelium seems largely uniform in the mouse 
until  E12.  How  the  different  subtypes  of  TECs  are 
generated is unclear, but it is well established that the E12 
thymic  anlage  contains  cells  that  can  clonally  generate 
both cTECs and mTECs. As fetal TEC progenitors can 
reconstitute  a  fully  functional  thymus  [8-11], directed 
differentiation  of  ES/iPS  cells  to  an  early  fetal 
developmental stage might suffice. This goal of generating 
an  early  fetal  progenitor  stands  in  sharp  contrast  to 
efforts to generate other more mature cell types, such a 
cardiomyocytes,  hepatocytes  and  pancreatic  islet  cells 
[1,4].
The success thus far in quantitative differentiation of ES 
cells into pancreatic b cells, cardiomyocytes, neurons and 
other  lineages  relies  on  mimicking  the  sequential 
developmental states in vivo in ES cells in vitro [1,4,37-
39].  As  developmental  cell  states  are  induced  by 
morphogen  gradients,  directed  differentiation  relies  on 
the application of these same state-specific morphogens 
to  ES  cultures.  Surprisingly,  a  recent  report  claimed 
generation  of  TECs  from  mouse  ES  cells  through  the 
direct application of terminal thymic maturation signals 
Figure 1: Schematic representation of potential applications of human induced pluripotent stem (iPS) cells-derived thymic epithelial 
cells (TECs). Gray compartments = decreased cell number and function; black cellular compartments = normal cell number and function.
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protocol  was  not  reported,  nor  was  the  presence  of 
alternative lineages assessed, and we have not been able 
to reproduce this approach in human pluripotent cells. 
Theoretically,  directed  differentiation  of  TECs  should 
proceed by generation of definitive endoderm, followed 
by  patterning  into  pharyngeal  or  anterior  foregut 
endoderm  [41].  Subsequently,  third  pharyngeal  pouch 
and  then  TEC  cell  fates  should  be  specified.  Although 
definitive  endoderm  has  been  generated  [42-44], 
subsequent  specification  of  this  germ  layer  to  anterior 
and pharyngeal fates has remained a challenge. We have 
recently  shown  that  dual  inhibition  of  transforming 
growth factor-b/bone morphogenetic protein signaling of 
human  ES  and  iPS-derived  definitive  endoderm  led  to 
the quantitative generation of anterior foregut endoderm, 
which  could  subsequently  differentiate  into  cells 
expressing markers of parathyroids and lung [45]. It is 
likely that this strategy will serve as a useful platform for 
the generation of tissues derived from anterior foregut 
endoderm, including but not limited to the thymus.
Conclusions
While  the  potential  clinical  and  scientific  benefits  of 
TECs derived from human pluripotent are great, it has 
not yet been possible to generate TECs from human ES 
or iPS cells. Given recent progress in the generation of 
derivatives of definitive endoderm, however, we antici-
pate significant progress in this area in the near future.
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